95% CI

:   95% confidence interval

APIS

:   a priori anticipated information size

COX‐2

:   cyclooxygenase‐2

HR

:   hazard ratio

IHC

:   immunohistochemistry

OR

:   odds ratio

PRISMA

:   Preferred Reporting Items for Systematic Reviews and Meta‐Analyses

PTGS

:   prostaglandin‐endoperoxide synthase

RRR

:   relative risk reduction

TSA

:   trial sequential analysis

Osteosarcoma is the most frequent primary bone sarcoma that occurs mainly in children and adolescents [1](#feb412560-bib-0001){ref-type="ref"}. Approximately 4.4 per million are diagnosed with osteosarcoma every year [1](#feb412560-bib-0001){ref-type="ref"}, [2](#feb412560-bib-0002){ref-type="ref"}. Osteogenic sarcoma consists of several main histotypes: osteoblastic, chondroblastic, and fibroblastic osteosarcoma [3](#feb412560-bib-0003){ref-type="ref"}. Osteogenic osteosarcoma is the most common pathological subtype [3](#feb412560-bib-0003){ref-type="ref"}. Although the biology of osteosarcoma is complex, treatment options have not significantly changed over the past several decades [4](#feb412560-bib-0004){ref-type="ref"}. Osteosarcoma can be caused by other types of cancer and some environmental factors such as viruses and radiation [5](#feb412560-bib-0005){ref-type="ref"}. This rare disease is treated by advanced surgery and adjuvant/neoadjuvant chemotherapy [6](#feb412560-bib-0006){ref-type="ref"}, [7](#feb412560-bib-0007){ref-type="ref"}. Current treatment for osteosarcoma achieves a 5‐year survival rate of 20% to 30% in metastatic or recurrent osteosarcoma patients [8](#feb412560-bib-0008){ref-type="ref"}. When diagnosed, 40% of metastasis occurs in osteosarcoma patients at an advanced stage [9](#feb412560-bib-0009){ref-type="ref"}.

Increasing evidence shows that molecular mechanisms are correlated with the development, progression, and prognosis of osteosarcoma [10](#feb412560-bib-0010){ref-type="ref"}, [11](#feb412560-bib-0011){ref-type="ref"}, [12](#feb412560-bib-0012){ref-type="ref"}, [13](#feb412560-bib-0013){ref-type="ref"}. Cyclooxygenase (COX), also called prostaglandin‐endoperoxide synthase (PTGS), is a key enzyme catalyzing the conversion of arachidonic acid to prostaglandin. COX has two isoforms: constitutive COX (COX‐1) and inducible COX (COX‐2) [14](#feb412560-bib-0014){ref-type="ref"}. The COX‐2 gene, encoding the inducible isozyme, is activated by growth factors, inflammatory stimuli, or carcinogenic factors, and its expression is usually undetectable in most normal tissues [15](#feb412560-bib-0015){ref-type="ref"}, [16](#feb412560-bib-0016){ref-type="ref"}. Furthermore, COX‐2 is involved in the regulation of cell proliferation and apoptosis, stimulation of angiogenesis, and invasion [17](#feb412560-bib-0017){ref-type="ref"}, [18](#feb412560-bib-0018){ref-type="ref"}, [19](#feb412560-bib-0019){ref-type="ref"}. Some studies suggest that COX‐2 expression may correlate with the development and progression of several types of human malignancies [20](#feb412560-bib-0020){ref-type="ref"}, [21](#feb412560-bib-0021){ref-type="ref"}, [22](#feb412560-bib-0022){ref-type="ref"}. The expression of COX‐2 is related to an increased risk of skin cancer [23](#feb412560-bib-0023){ref-type="ref"}, as well as to tumor size, lymph node metastasis, and poor prognosis in breast [24](#feb412560-bib-0024){ref-type="ref"} and colorectal and ovarian cancers [25](#feb412560-bib-0025){ref-type="ref"}, [26](#feb412560-bib-0026){ref-type="ref"}. Nevertheless, no significant role of the expression of COX‐2 was found on the survival of patients with non‐small‐cell lung cancer [27](#feb412560-bib-0027){ref-type="ref"}. Importantly, COX‐2 may regulate the genesis and progression of osteosarcoma [28](#feb412560-bib-0028){ref-type="ref"} and COX‐2 expression has been reported in patients with osteosarcoma [29](#feb412560-bib-0029){ref-type="ref"}, [30](#feb412560-bib-0030){ref-type="ref"}, [31](#feb412560-bib-0031){ref-type="ref"}, [32](#feb412560-bib-0032){ref-type="ref"}. In earlier studies, the percentage of osteosarcoma patients with COX‐2‐positive expression ranged from 16.7% to 81.2% [33](#feb412560-bib-0033){ref-type="ref"}, [34](#feb412560-bib-0034){ref-type="ref"}. Therefore, further investigations on the clinical significance of COX‐2 expression in osteosarcoma patients are required.

Benign bone tumors include osteochondroma, osteoma, osteoid osteoma, osteoblastoma, giant cell tumor, aneurysmal bone cyst, fibrous dysplasia, and enchondroma [35](#feb412560-bib-0035){ref-type="ref"}. Osteochondroma is the most common nonmalignant bone tumor, accounting for approximately 35% of all benign bone tumors [35](#feb412560-bib-0035){ref-type="ref"}. However, the malignant transformation into osteosarcoma has not been sufficiently studied, and its mechanism is still unclear [36](#feb412560-bib-0036){ref-type="ref"}. The sample sizes of the individual studies were generally small [29](#feb412560-bib-0029){ref-type="ref"}, [30](#feb412560-bib-0030){ref-type="ref"}, [31](#feb412560-bib-0031){ref-type="ref"}, [32](#feb412560-bib-0032){ref-type="ref"}, [33](#feb412560-bib-0033){ref-type="ref"}, [34](#feb412560-bib-0034){ref-type="ref"}, which might have led to a lack of power in the statistical analysis.

In this study, the present meta‐analysis integrated all available publications in a larger population to evaluate whether COX‐2 expression is associated with an increased risk of osteosarcoma in a comparison between osteosarcoma and benign osteochondroma cases. Additionally, we analyzed the possible clinicopathological and prognostic significance of COX‐2 expression in patients with osteosarcoma.

Materials and methods {#feb412560-sec-0002}
=====================

Search strategy {#feb412560-sec-0003}
---------------

A systematic search was performed of different electronic databases, including PubMed, Embase, EBSCO, Wanfang, and CNKI, for eligible papers published before June 2017. The following key words and search terms were used: (COX‐2 OR COX2 OR Cyclooxygenase‐2 OR PTGS2 OR Prostaglandin Synthase) AND (expression OR expressed) AND (osteosarcoma OR osteogenic sarcoma). Moreover, the reference lists of the included publications were also retrieved to find other potentially relevant studies.

Selection criteria {#feb412560-sec-0004}
------------------

The following inclusion criteria were applied in this meta‐analysis: (a) confirmation of osteosarcoma by histopathological examination; (b) COX‐2 protein expression tissue analyses using immunohistochemistry (IHC); (c) studies with complete information concerning the rate of COX‐2 protein expression in malignant and benign osteochondroma; (d) studies with sufficient information to assess the correlation of COX‐2 expression with clinical characteristics of patients with osteosarcoma; and (e) studies providing sufficient information to evaluate the prognostic effect of COX‐2 expression in osteosarcoma by multivariate analysis. Only the complete publications with more extensive information or larger populations were included when the authors had published more than one article using overlapping study populations.

Data extraction and study selection {#feb412560-sec-0005}
-----------------------------------

The following data were extracted from the eligible publications: the last name of the first author; year of publication; country; ethnicity; case number (osteosarcoma and benign osteochondroma); immunohistochemical staining patterns; cutoff values; median or mean years; tumor stage; frequency of COX‐2 expression; clinical characteristics, such as age (≥20 years vs. ≤20 years), gender (male vs. female), tumor location (femur vs. nonfemur), cancer histology (osteogenic osteosarcoma vs. nonosteogenic osteosarcoma), tumor grade (grade 3--4 vs. grade 1--2), clinical stage (stage 3--4 vs. stage 1--2), necrosis (≥90% vs. \<90%), and metastasis (yes vs. no); and the prognosis from multivariate analysis. We analyzed data from 2 × 2 tables. The quality of the eligible studies was in accordance with the guidelines of the Cochrane Collaboration and the Preferred Reporting Items for Systematic Reviews and Meta‐Analyses (PRISMA) statement criteria [37](#feb412560-bib-0037){ref-type="ref"}. A total number of 391 publications were found: 83 records in PubMed, 96 records in Embase, 77 records in EBSCO, 75 records in Wanfang, and 60 records in CNKI. Final 23 studies were identified in this meta‐analysis. To categorize a patient as COX‐2‐positive or COX‐2‐negative, the COX‐2 expression, determined using IHC staining, was considered positive or negative based on the cutoff values of the original articles.

Statistical analysis {#feb412560-sec-0006}
--------------------

Data analysis was performed using the [stata]{.smallcaps} software (version 12.0; Stata Corporation, College Station, TX, USA). The combined odds ratios (ORs) and their 95% confidence intervals (95% CIs) were calculated to estimate the relationships of COX‐2 expression in osteosarcoma and benign osteochondroma. The correlations of COX‐2 expression with the clinical characteristics of osteosarcoma patients were also analyzed using the overall ORs and their 95% CIs. The overall hazard ratios (HRs) with their 95% CIs were determined to evaluate the prognostic effect of COX‐2 expression in osteosarcoma patients for multivariate analysis. Heterogeneity among the studies was detected using the Cochran\'s Q statistic [38](#feb412560-bib-0038){ref-type="ref"}. The random‐effects model was used in this meta‐analysis. Subgroup, meta‐regression, and sensitivity analyses were conducted of the results with substantial heterogeneity (*P *\<* *0.1), to explain the potential sources of heterogeneity [39](#feb412560-bib-0039){ref-type="ref"}, [40](#feb412560-bib-0040){ref-type="ref"}. The possible publication bias was measured using Egger\'s test in more than eight studies [41](#feb412560-bib-0041){ref-type="ref"}.

Trial sequential analysis {#feb412560-sec-0007}
-------------------------

Trial sequential analysis (TSA) was performed to reduce type I error and to assess the required information size for determination of the statistical significance [42](#feb412560-bib-0042){ref-type="ref"}, [43](#feb412560-bib-0043){ref-type="ref"}. In the meta‐analysis, the type I and type II errors were considered to be 5% and 20%, respectively. The relative risk reduction (RRR) was set to be of 20% for the outcome, and a statistical test power of 80% was defined. The cumulative *Z*‐curve crossed the trial sequential monitoring boundary or the required study population information, which suggested that the conclusion drawn in the meta‐analysis was positive; otherwise, more studies with larger sample sizes were indicated to be necessary for consistency in the evidence [44](#feb412560-bib-0044){ref-type="ref"}, [45](#feb412560-bib-0045){ref-type="ref"}.

Results {#feb412560-sec-0008}
=======

Characteristics of the relevant publications {#feb412560-sec-0009}
--------------------------------------------

Figure [1](#feb412560-fig-0001){ref-type="fig"} illustrates the above‐described search strategy. After the search of the relevant databases, 23 studies with a total of 1084 patients with osteosarcoma and 247 patients with benign osteochondroma were eventually included in the current meta‐analysis. All these studies published from 2003 to 2016 had used IHC analysis of COX‐2 expression [29](#feb412560-bib-0029){ref-type="ref"}, [30](#feb412560-bib-0030){ref-type="ref"}, [31](#feb412560-bib-0031){ref-type="ref"}, [32](#feb412560-bib-0032){ref-type="ref"}, [33](#feb412560-bib-0033){ref-type="ref"}, [34](#feb412560-bib-0034){ref-type="ref"}, [46](#feb412560-bib-0046){ref-type="ref"}, [47](#feb412560-bib-0047){ref-type="ref"}, [48](#feb412560-bib-0048){ref-type="ref"}, [49](#feb412560-bib-0049){ref-type="ref"}, [50](#feb412560-bib-0050){ref-type="ref"}, [51](#feb412560-bib-0051){ref-type="ref"}, [52](#feb412560-bib-0052){ref-type="ref"}, [53](#feb412560-bib-0053){ref-type="ref"}, [54](#feb412560-bib-0054){ref-type="ref"}, [55](#feb412560-bib-0055){ref-type="ref"}, [56](#feb412560-bib-0056){ref-type="ref"}, [57](#feb412560-bib-0057){ref-type="ref"}, [58](#feb412560-bib-0058){ref-type="ref"}, [59](#feb412560-bib-0059){ref-type="ref"}, [60](#feb412560-bib-0060){ref-type="ref"}, [61](#feb412560-bib-0061){ref-type="ref"}, [62](#feb412560-bib-0062){ref-type="ref"}. Eleven of these eligible studies compared the expression of COX‐2 between osteosarcoma and benign osteochondroma. The associations between COX‐2 expression and the clinical features of patients with osteosarcoma were examined in 21 studies. Two original studies reported the prognostic role of COX‐2 expression using multivariate analysis in patients with osteosarcoma. The general characteristics of the eligible papers are listed in Table [1](#feb412560-tbl-0001){ref-type="table"} and Table [2](#feb412560-tbl-0002){ref-type="table"}.

![Flow diagram of the study selection.](FEB4-9-226-g001){#feb412560-fig-0001}

###### 

Basic characteristics of the included publications. E+, positive expression status; IHC, immunohistochemistry; MA, multivariate analysis; N, study population; NA, not applicable

  First author                                            Country   Ethnicity    Age     Stage   Location    Osteosarcoma   Osteochondroma   Clinical features   MA‐survival   IHC cutoff (positivity)
  ------------------------------------------------------- --------- ------------ ------- ------- ----------- -------------- ---------------- ------------------- ------------- -------------------------
  Dickens [46](#feb412560-bib-0046){ref-type="ref"}       USA       Caucasians   NA      NA      Cytoplasm   99 (66.7)                       Yes                 No            25%
  Jiang [47](#feb412560-bib-0047){ref-type="ref"}         China     Asians       NA      NA      Cytoplasm   31 (67.7)                       Yes                 No            5%
  Zhu [48](#feb412560-bib-0048){ref-type="ref"}           China     Asians       25.5    NA      Cytoplasm   31 (61.3)      30 (6.7)         Yes                 No            5%
  Hosono [34](#feb412560-bib-0034){ref-type="ref"}        Japan     Asians       29      NA      Cytoplasm   30 (16.7)                       Yes                 No            10%
  Masi [33](#feb412560-bib-0033){ref-type="ref"}          Italy     Caucasians   19      NA      Cytoplasm   42 (59.5)                       Yes                 No            20%
  Ou [49](#feb412560-bib-0049){ref-type="ref"}            China     Asians       18.6    1--3    Cytoplasm   49 (77.6)      20 (35)          Yes                 No            5%
  Wang [50](#feb412560-bib-0050){ref-type="ref"}          China     Asians       18.68   NA      Cytoplasm   40 (67.5)      20 (15)          No                  No            5%
  Rodriguez [32](#feb412560-bib-0032){ref-type="ref"}     USA       Mix          17      NA      NA          36 (47.2)                       Yes                 No            10%
  Geng [51](#feb412560-bib-0051){ref-type="ref"}          China     Asians       19.3    1--3    Cytoplasm   59 (69.5)                       Yes                 No            10%
  Zhan [52](#feb412560-bib-0052){ref-type="ref"}          China     Asians       19      1--3    Cytoplasm   38 (57.9)      20 (25)          Yes                 No            5%
  Urakawa [31](#feb412560-bib-0031){ref-type="ref"}       Japan     Asians       15      2       NA          51 (23.5)                       Yes                 Yes           80%
  Liu [53](#feb412560-bib-0053){ref-type="ref"}           China     Asians       21.8    2--3    Cytoplasm   50 (70)        20 (30)          Yes                 No            5%
  Liao [54](#feb412560-bib-0054){ref-type="ref"}          China     Asians       42.1    1--3    Cytoplasm   57 (70.2)      18 (11.1)        Yes                 No            10%
  Huang [55](#feb412560-bib-0055){ref-type="ref"}         China     Asians       NA      1--3    Cytoplasm   37 (86.5)                       Yes                 No            30%
  Boulytcheva [30](#feb412560-bib-0030){ref-type="ref"}   Russia    Caucasians   NA      1--4    Cytoplasm   34 (32.4)                       Yes                 Yes           10%
  Li [56](#feb412560-bib-0056){ref-type="ref"}            China     Asians       19      1--3    Cytoplasm   85 (62.4)      20 (15)          Yes                 No            10%
  Xu [57](#feb412560-bib-0057){ref-type="ref"}            China     Asians       20      1--3    Cytoplasm   28 (78.6)      25 (36)          Yes                 No            5%
  Ma [58](#feb412560-bib-0058){ref-type="ref"}            China     Asians       NA      1--3    Cytoplasm   45 (80)                         Yes                 No            10%
  Duan [29](#feb412560-bib-0029){ref-type="ref"}          China     Asians       NA      NA      Cytoplasm   30 (73.3)      20 (25)          Yes                 No            0%
  Chen [59](#feb412560-bib-0059){ref-type="ref"}          China     Asians       18.5    2--3    Cytoplasm   49 (49)                         Yes                 No            10%
  Meng [60](#feb412560-bib-0060){ref-type="ref"}          China     Asians       NA      NA      Cytoplasm   52 (71.2)      40 (35)          No                  No            10%
  Lian [61](#feb412560-bib-0061){ref-type="ref"}          China     Asians       21.1    2--3    Cytoplasm   35 (82.9)      14 (14.3)        Yes                 No            0%
  Zhu [62](#feb412560-bib-0062){ref-type="ref"}           China     Asians       27.5    NA      Cytoplasm   76 (68.4)                       Yes                 No            5%

John Wiley & Sons, Ltd

###### 

Basic characteristics of the eligible studies with clinical characteristics

  First author                                            \>/= 20 years   \</= 20 years   Male    Female   Femur   Nonfemur   Osteogenic OS   Nonosteogenic OS   Grade 3--4   Grade 1--2   Stage 3--4   Stage 1--2   Necrosis   No      Metastasis   No
  ------------------------------------------------------- --------------- --------------- ------- -------- ------- ---------- --------------- ------------------ ------------ ------------ ------------ ------------ ---------- ------- ------------ -------
  Dickens [46](#feb412560-bib-0046){ref-type="ref"}                                       11/24   15/21                                                                                                              6/9        8/18    24/32        23/35
  Jiang [47](#feb412560-bib-0047){ref-type="ref"}                                                                                                                                                                                       14/17        7/14
  Zhu [48](#feb412560-bib-0048){ref-type="ref"}                                           13/22   6/9                                                            9/10         10/21                                                     14/17        5/14
  Hosono [34](#feb412560-bib-0034){ref-type="ref"}        1/16            4/14            4/16    1/14     4/18    1/12       0/16            5/14               5/26         0/4                                                                    
  Masi [33](#feb412560-bib-0033){ref-type="ref"}                                                                                                                 23/32        2/10                                                                   
  Ou [49](#feb412560-bib-0049){ref-type="ref"}                                                                                15/19           23/30                                        12/13        26/36                           12/13        26/36
  Rodriguez [32](#feb412560-bib-0032){ref-type="ref"}                                     7/8     3/7      9/21    8/15       6/8             11/28                                                                  7/14       10/22   6/10         11/26
  Geng [51](#feb412560-bib-0051){ref-type="ref"}                                                                              23/35           18/24                                                                                     7/8          34/51
  Zhan [52](#feb412560-bib-0052){ref-type="ref"}                                                                                                                                           8/11         14/27                                        
  Urakawa [31](#feb412560-bib-0031){ref-type="ref"}       5/20            7/31            9/33    3/18                                                                                                               7/18       5/33    8/18         4/33
  Liu [53](#feb412560-bib-0053){ref-type="ref"}                                                                                                                                            14/15        21/35                                        
  Liao [54](#feb412560-bib-0054){ref-type="ref"}                                                                              15/22           25/35                                        22/23        18/34                                        
  Huang [55](#feb412560-bib-0055){ref-type="ref"}                                                                             12/14           19/23                                        10/11        22/26                           15/16        17/21
  Boulytcheva [30](#feb412560-bib-0030){ref-type="ref"}                                                                                                                                                                                 6/11         5/23
  Li [56](#feb412560-bib-0056){ref-type="ref"}                                                                                                                   25/31        28/54        21/25        32/60                           36/48        17/37
  Xu [57](#feb412560-bib-0057){ref-type="ref"}                                                                                11/14           11/14                                        8/8          14/20                                        
  Ma [58](#feb412560-bib-0058){ref-type="ref"}                                            29/37   7/8                         23/31           12/14                                        12/13        24/32                                        
  Duan [29](#feb412560-bib-0029){ref-type="ref"}                                                                              9/13            13/17              7/9          15/21                                                                  
  Chen [59](#feb412560-bib-0059){ref-type="ref"}                                                                                                                                                                     12/29      12/20                
  Lian [61](#feb412560-bib-0061){ref-type="ref"}                                          18/22   11/13                                                                                    12/12        17/23                           22/24        7/11
  Zhu [62](#feb412560-bib-0062){ref-type="ref"}                                                                                                                  23/25        29/51                                                                  

E, positive expression status; N, study population; NA, not applicable; OS, osteosarcoma.

John Wiley & Sons, Ltd

Association between COX‐2 expression and osteosarcoma development {#feb412560-sec-0010}
-----------------------------------------------------------------

The data from 11 comparative studies, including of 495 patients with osteosarcoma vs. 247 benign osteochondroma patients, revealed that COX‐2 expression was significantly more increased in osteosarcoma than in benign osteochondroma (OR = 7.66, 95% CI = 5.25--11.17, *P *\<* *0.001) (Fig. [2](#feb412560-fig-0002){ref-type="fig"}).

![Forest plot of the association of COX‐2 immunoexpression between osteosarcoma and benign osteochondroma (OR = 7.66, *P *\<* *0.001).](FEB4-9-226-g002){#feb412560-fig-0002}

Association of COX‐2 expression with tumor grade and clinical stage in osteosarcoma {#feb412560-sec-0011}
-----------------------------------------------------------------------------------

Six studies with 294 osteosarcoma patients found a significant relationship between COX‐2 expression and tumor grade (high grade vs. low grade: OR = 4.81, 95% CI = 2.48--9.32, *P *\<* *0.001) (Fig. [3](#feb412560-fig-0003){ref-type="fig"}).

![Forest plot of the correlation of COX‐2 immunoexpression with the tumor grade (OR = 4.81, *P *\<* *0.001) and clinical stage (OR = 4.89, *P *\<* *0.001).](FEB4-9-226-g003){#feb412560-fig-0003}

Additionally, nine studies with 424 osteosarcoma patients discovered a significant correlation was observed between COX‐2 expression and clinical stage (stage 3--4 vs. stage 1--2: OR = 4.89, 95% CI = 2.57--9.30, *P *\<* *0.001) (Fig. [3](#feb412560-fig-0003){ref-type="fig"}).

Association of COX‐2 expression with metastasis in osteosarcoma {#feb412560-sec-0012}
---------------------------------------------------------------

The results obtained in 11 studies with 515 osteosarcoma patients demonstrated that COX‐2 expression was significantly associated with metastasis in osteosarcoma (OR = 3.53, 95% CI = 2.27--5.51, *P *\<* *0.001) (Fig. [4](#feb412560-fig-0004){ref-type="fig"}).

![Forest plot of the correlation of COX‐2 immunoexpression with metastasis (OR = 3.53, *P *\<* *0.001).](FEB4-9-226-g004){#feb412560-fig-0004}

Prognostic role of COX‐2 expression for multivariate analysis in osteosarcoma {#feb412560-sec-0013}
-----------------------------------------------------------------------------

Cyclooxygenase‐2 expression was linked to worse metastasis‐free survival (*P *=* *0.029) in 51 osteosarcoma patients [31](#feb412560-bib-0031){ref-type="ref"}. Moreover, Boulytcheva *et al*. [30](#feb412560-bib-0030){ref-type="ref"} reported that COX‐2 expression in 34 patients with osteosarcoma was associated with poor overall survival and relapse‐free survival (*P *\<* *0.05). Nonetheless, additional studies are needed to further validate the findings concerning the prognostic effect of COX‐2 expression established by multivariate survival analysis in osteosarcoma.

Heterogeneity and publication bias {#feb412560-sec-0014}
----------------------------------

No significant heterogeneity was detected in our meta‐analysis (all *Ps *\> 0.1) (Figs [2](#feb412560-fig-0002){ref-type="fig"}, [3](#feb412560-fig-0003){ref-type="fig"}, [4](#feb412560-fig-0004){ref-type="fig"}, [5](#feb412560-fig-0005){ref-type="fig"}, [6](#feb412560-fig-0006){ref-type="fig"}).

![Forest plot of the possible publication bias determined using Egger\'s test (osteosarcoma vs. benign osteochondroma: *P *\<* *0.001), cancer histology (*P *=* *0.958), clinical stage (*P *=* *0.397), and metastasis (*P *=* *0.186).](FEB4-9-226-g005){#feb412560-fig-0005}

![Trial sequential analysis of COX‐2 immunoexpression in osteosarcoma vs. benign osteochondroma. The cumulative Z‐curve crossed the trial sequential monitoring boundary, suggesting that the result was conclusive.](FEB4-9-226-g006){#feb412560-fig-0006}

Egger\'s test was applied to measure the publication bias, and significant heterogeneity was found in the comparison of osteosarcoma and benign osteochondroma (*P *\<* *0.001) (Fig. [5](#feb412560-fig-0005){ref-type="fig"}). However, no evidence of publication bias was found between COX‐2 expression and metastasis, clinical stage, or cancer histology in osteosarcoma (*P *\>* *0.05) (Fig. [5](#feb412560-fig-0005){ref-type="fig"}).

Trial sequential analysis {#feb412560-sec-0015}
-------------------------

Based on the a priori anticipated information size (APIS) method, when osteosarcoma was compared to benign osteochondroma (Fig. [6](#feb412560-fig-0006){ref-type="fig"}), the patients with high‐grade cancer were compared to patients with low‐grade cancer (Fig. [7](#feb412560-fig-0007){ref-type="fig"}), advanced‐stage patients were compared to early‐stage patients (Fig. [8](#feb412560-fig-0008){ref-type="fig"}), and the patients with metastasis were compared to patients without metastasis (Fig. [9](#feb412560-fig-0009){ref-type="fig"}). The cumulative *Z*‐curve crossed the trial sequential monitoring boundary for the above analyses, which suggested that these results were reliable and firm.

![Trial sequential analysis of COX‐2 immunoexpression in relation to tumor grade. The cumulative *Z*‐curve crossed the trial sequential monitoring boundary, suggesting that the result was reliable.](FEB4-9-226-g007){#feb412560-fig-0007}

![Trial sequential analysis of COX‐2 immunoexpression in relation to clinical stage. The cumulative Z‐curve crossed the trial sequential monitoring boundary, suggesting that the result was reliable.](FEB4-9-226-g008){#feb412560-fig-0008}

![Trial sequential analysis of COX‐2 immunoexpression in relation to metastasis. The cumulative Z‐curve crossed the trial sequential monitoring boundary, suggesting that the result was conclusive.](FEB4-9-226-g009){#feb412560-fig-0009}

Association of COX‐2 expression with age, gender, or tumor location in osteosarcoma {#feb412560-sec-0016}
-----------------------------------------------------------------------------------

We explored whether the expression of COX‐2 was correlated with the clinical characteristics of patients with osteosarcoma. The results showed that COX‐2 expression was not associated with age (two studies with 81 cases: ≥ 20 years vs. ≤ 20 years), gender (seven studies with 252 cases: male vs. female), or tumor location (two studies with 66 cases: femur vs. nonfemur) of osteosarcoma (OR = 0.56, 95% CI = 0.09--3.49, *P *=* *0.534; OR = 1.05, 95% CI = 0.47--2.37, *P *=* *0.903; OR = 1.06, 95% CI = 0.26--4.41, *P *=* *0.933, respectively) (Fig. [10](#feb412560-fig-0010){ref-type="fig"}).

![Forest plot of the association of COX‐2 immunoexpression with age factor, gender, and tumor location (*P *\>* *0.1).](FEB4-9-226-g010){#feb412560-fig-0010}

Association of COX‐2 expression with histology and necrosis in osteosarcoma {#feb412560-sec-0017}
---------------------------------------------------------------------------

The results showed no significant correlation between COX‐2 expression and cancer histology (nine studies with 371 cases: osteogenic osteosarcoma vs. nonosteogenic osteosarcoma: OR = 0.87, 95% CI = 0.52--1.45, *P *=* *0.583) (Fig. [11](#feb412560-fig-0011){ref-type="fig"}) or necrosis (four studies with 163 cases: ≥ 90% vs. \< 90%: OR = 1.39, 95% CI = 0.54--3.56, *P *=* *0.491) (Fig. [11](#feb412560-fig-0011){ref-type="fig"}).

![Forest plot of the correlation of COX‐2 immunoexpression with cancer histology and necrosis (*P *\>* *0.1).](FEB4-9-226-g011){#feb412560-fig-0011}

Discussion {#feb412560-sec-0018}
==========

Using the IHC method, the authors of a number of earlier studies have demonstrated that COX‐2 is frequently expressed in a variety of human cancers, including lung cancer [30](#feb412560-bib-0030){ref-type="ref"}, breast carcinoma [20](#feb412560-bib-0020){ref-type="ref"}, colorectal cancer [63](#feb412560-bib-0063){ref-type="ref"}, and nasopharyngeal carcinoma [64](#feb412560-bib-0064){ref-type="ref"}. COX‐2 immunoexpression was also detected in osteosarcoma [29](#feb412560-bib-0029){ref-type="ref"}, [30](#feb412560-bib-0030){ref-type="ref"}. The meta‐analysis of Jiao *et al*. [65](#feb412560-bib-0065){ref-type="ref"} involving 14 studies reported that COX‐2 expression was correlated with the clinical stage and metastasis of osteosarcoma. However, the meta‐analysis of Wang *et al*. involving nine studies established that COX‐2 expression was not associated with the metastasis and clinical stage of osteosarcoma [66](#feb412560-bib-0066){ref-type="ref"}. To compare whether COX‐2 expression was different in osteosarcoma and benign osteochondroma, the results from 11 studies (495 osteosarcomas vs. 247 benign osteochondromas) demonstrated that COX‐2 expression in osteosarcoma was notably higher than in benign osteochondroma (OR = 7.66, *P *\<* *0.001), which suggested that COX‐2 expression as a potential marker using the IHC method could distinguish osteosarcoma and benign osteochondroma. TSA revealed that true‐positive results were obtained in the comparative analysis of osteosarcoma and benign osteochondroma.

On further evaluation, the relationship between COX‐2 expression and the clinical characteristics of patients with osteosarcoma showed no significant correlation of COX‐2 expression with age, gender, tumor location, cancer histology, and necrosis across each study (Figs [10](#feb412560-fig-0010){ref-type="fig"} and [11](#feb412560-fig-0011){ref-type="fig"}). And these results from all pooled studies remained constant. COX‐2 expression was not associated with tumor grade in osteosarcoma [29](#feb412560-bib-0029){ref-type="ref"}, [34](#feb412560-bib-0034){ref-type="ref"}, but Masi *et al*. [33](#feb412560-bib-0033){ref-type="ref"} reported that COX‐2 expression was correlated with tumor grade. Pooled data from six studies with 294 cases revealed that COX‐2 expression was positively linked to tumor grade (OR = 4.81) and clinical stage (OR = 4.89). Dickens *et al*. [46](#feb412560-bib-0046){ref-type="ref"} found no significant association between COX‐2 expression and metastatic status. Rodriguez 2008 *et al*. also reported that no correlation existed between COX‐2 expression and metastasis in osteosarcoma [32](#feb412560-bib-0032){ref-type="ref"}. Conversely, Urakawa *et al*. [31](#feb412560-bib-0031){ref-type="ref"} reported that the expression of COX‐2 was significantly related to the metastatic status of osteosarcoma. Further analysis from 11 studies with 515 osteosarcoma patients revealed the presence of a positive association between COX‐2 expression and the metastatic status of osteosarcoma in a larger population. The above‐mentioned analyses suggest that the expression of COX‐2 may play an important role in disease progression and metastasis in patients with osteosarcoma. No evidence of substantial heterogeneity was available concerning the clinical features. Further TSA revealed that future additional studies are not essential. Therefore, the results of our analysis are conclusive.

The multivariate analysis showed that COX‐2 expression was associated with worse prognosis in metastasis‐free survival (5 years) [31](#feb412560-bib-0031){ref-type="ref"}, overall survival, and relapse‐free survival [30](#feb412560-bib-0030){ref-type="ref"}, which indicated that COX‐2 expression might become a potential prognostic marker. Additional clinical research of larger sample sizes using multivariate analysis in patients with osteosarcoma is necessary to confirm the prognostic significance of COX‐2 expression.

The present meta‐analysis has several limitations. First, the patients included in the analyses were mainly Asians and Caucasians, but the shares of other ethnic groups, such as the African population, were insufficient. Second, publication bias was detected in the comparison of osteosarcoma and benign osteochondroma. Papers with positive conclusions were more easily published than articles with negative conclusions. In addition, publications of other styles, such as conference abstracts, were lacking due to insufficient information. Third, more studies using multivariate analysis of COX‐2 expression are needed to confirm the prognostic effect in different ethnic groups. Finally, the cutoff values of COX‐2 expression of the eligible studies were different. Thus, in the future, whether COX‐2 expression is positive or negative should be defined based on common standards set.

In conclusion, the present findings suggest that COX‐2 immunoexpression is significantly higher in osteosarcoma than in benign osteochondroma. Additionally, COX‐2 expression is associated with tumor grade, clinical stage, and metastasis of osteosarcoma but is not correlated with age, gender, tumor location, histology, or necrosis. The expression of COX‐2 may serve as a prognostic indicator for the multivariate analysis of metastasis‐free, overall, and relapse‐free survival. Conducting additional, well‐designed, prospective studies that investigate large populations in the future is essential to further validate the prognostic role of COX‐2 expression.
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